

**REMARKS**

This amendment adds a sequence listing identifier to the present application. Filed concurrently herewith is a Sequence Listing which corresponds to the sequence identifier added herein. This submission includes no new matter. Applicants respectfully submit that this application complies with 37 C.F.R. 1.821-1.825.

Applicants now believe that in light of the foregoing amendment to the specification and submission of the sequence listing the application is in proper condition for allowance. Should Examiner Royds feel that any other point requires consideration, then she is cordially invited to contact the undersigned.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Date: December 3, 2008

  
John F. Levis  
Attorney for Applicants  
Reg. No. 34,210  
Phone: 203-677-3782